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Background: Although neoadjuvant chemotherapy (NCT) is widely used, it is not clear which subgroup of locally
advanced non-small-cell lung cancer (NSCLC) patients should be treated with this approach, and if a particular
benefit associated with NCT exists. In this study, we aimed to investigate the potential correlates of benefit from
NCT in patients with NSCLC.
Methods: All randomized clinical trials (RCTs) utilizing a NCT arm (without radiotherapy) versus a control arm
before surgery were included for metaregression analysis. All regression analyses were weighed for trial size.
Separate analyses were conducted for trials recruiting patients with different stages of disease. Previously published
measures of treatment efficacy were used for the purpose of this study, regardless of being published in full text or
abstract form.
Results: A total of 14 RCTs, consisting of 3,615 patients, were selected. Histology, stage, various characteristics of
the NCT protocol, and different trial features including trial quality score were not associated with the benefit of
NCT. However, in trials of stage 3 disease only, there was a greater benefit in terms of reduction in mortality from
NCT, if protocols with three chemotherapeutics were used (B =−0.18, t =−5.25, P= 0.006).
Conclusions: We think that patients with stage 3 NSCLC are served better with NCT before surgery if protocols
with three chemotherapy agents or equally effective combinations are used. In addition, the effect of neoadjuvant
chemotherapy is consistent with regard to disease and patient characteristics. This finding should be tested in
future RCTs or individual patient data meta-analyses.
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Locally advanced cases of non-small-cell lung cancer
(NSCLC) constitute nearly a fifth of all NSCLC cases
[1,2]. Different standards exist for the treatment of lo-
cally advanced NSCLC, partially owing to the heteroge-
neous nature of this disease, and lack of consistent data
regarding treatment outcomes [2,3].
Although chemoradiotherapy and neoadjuvant chemo-
therapy (NCT) followed by surgery are two widely uti-
lized therapeutic approaches, NCT is still considered as* Correspondence: hbozcuk@gmail.com
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reproduction in any medium, provided the orexperimental, primarily because previous meta-analyses
have been inconclusive [2-7]. The last meta-analysis in
particular shows the benefit of NCT, but fails to point
out any special feature that is linked with the magnitude
of efficacy of NCT [8]. Therefore, from a practical point
of view, the important questions of which patients
should be treated with NCT, and whether there is any
superior type of NCT, still remain to be solved.
Related to these uncertainties regarding NCT, we
aimed to formulate hypotheses by looking into various
factors in previous randomized controlled trials (RCTs)
of NSCLC, which could be linked with the magnitude of
benefit from NCT, and thus, decided to conduct a
metaregression analysis to explore these factors.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Inclusion and exclusion of trials
All RCTs reported after 1966 with an NCT arm versus a
control arm (no NCT arm) before surgery were included
in this analysis. Two reviewers (HB, HA) selected RCTs
and extracted the data. All stages and full text or ab-
stract formats in English language literature only were
allowed. References of key articles were also referred to.
Hazard ratio (HR) was selected as summary data for
treatment efficiency for mortality, and used as given in
the last full text meta-analysis [7], or in the original pub-
lication of trials.
Non-randomized trials, as well as those with the inclu-
sion of radiotherapy before surgery (that is, induction
chemoradiotherapy trials) were excluded from the
analysis.Metaregression analysis
Hazard ratios for mortality for individual trials were log
transformed prior to being used as independent variables
in the linear regression analysis. All analyses were
weighed for the square root of individual trial size, as a
conservative measure of the (trial size adjusted) effect of
individual RCTs. However, for exploratory purposes, we
also tested the effect of trial size on the magnitude of
the associated hazard ratio of individual RCTs, and in
these analyses only, weighting for the square root of trial
size was not carried out. All trials, and also those with
stage 3 only, and mixed stage trials (stage 1 to 3), were
separately analyzed. A P value <0.05 was considered to
be significant.
A trial quality score was constructed using a scale
from 0 to 3, depending on three features; randomization
method (details given vs not given), stratification criteria
(reported vs not reported), and trial type (reported in full
text or abstract). So, 0 or 1 point for each trial feature
was totaled for the final trial quality score. We also drew
simple regression lines to illustrate the relationship be-
tween mortality and its predictors in clinically significant
subgroups as shown in the literature [9].Results
A total of 3,615 patients were represented in 14 RCTs
[10-26]. The median number of cases in each trial was
240.5 (26 to 624). Publication years varied between
1990 and 2010, and the median fraction of patients
with squamous cell cancer was 51.5%. A median of
three cycles of NCT (1 to 3) was used and the median
trial quality score was 1 (0 to 3). Six of the trials
(42.9% of all trials) addressed patients with stage 3
only disease, whereas eight trials (57.1%) included
patients with mixed stage (1 to 3) NSCLC. See Table 1
for individual RCT characteristics.None of the factors evaluated in the regression analysis
were linked with the efficacy of NCT. These factors were
histology, stage, type of platinum drug used, generation
and number of drugs in the protocol, number of cycles
administered before surgery, trial size, publication year,
origin of study and trial quality score. Only stage of dis-
ease interacted with the number of chemotherapy drugs
used to define the magnitude of NCT benefit. In stage 3
patients, reduced risk of mortality was associated with
the utilization of more frequent usage of three drug
regimes (B =−0.18, t =−5.25, P= 0.006). Table 2 shows
details of the regression analysis. The R2 value for the
association of log transformed hazard ratios for mortal-
ity with number of drugs in the protocol was 0.92 in
trials of stage 3 disease, and 0.27 in trials of mixed stages
(stages 1 to 3).
When only trials recruiting solely stage 3 patients were
considered, patients who received three drugs obtained a
35% reduction in hazard ratio for mortality compared to
those that received two to three drugs (hazard ratio =
0.53 in three drug trials, versus 0.81 in two to three
drug, heterogeneous treatment design trials). In the only
trial utilizing two drugs, neoadjuvant chemotherapy was
associated with a 19% increased risk of mortality over no
neoadjuvant chemotherapy (hazard ratio = 1.19).
The association with NCT benefit of protocols with
two or three chemotherapeutics in stage 3 or other
stages is represented in Figure 1. As only a minority of
the trials reported data on the toxicity of NCT, we did
not conduct a separate analysis to define correlates of
toxicity.
Discussion
We show for the first time that if NCT is to be used, a
higher number of chemotherapy drugs in the treatment
protocol may be associated with decreased mortality in
stage 3 NSCLC. However, in contrast, the most recent
individual patient data (IPD) meta-analysis failed to
demonstrate any factor that was associated with NCT
benefit in NSCLC [8]. It would be worthwhile to test the
validity of our hypothesis in this IPD meta-analysis data-
set. Of note, in the literature, a large NCT RCT with
three drug protocols containing third-generation agents
with at least three cycles of treatment and conducted
solely in stage 3 NSCLC patients is lacking. To have
such a RCT would obviously provide great insight into
the current management of stage 3 disease in NSCLC.
Third-generation three-drug protocols have previously
been tried in small trials in the setting of stage 3 NSCLC
[27,28]. Gemcitabine, vinorelbine, cisplatin (GVP) par-
ticularly, appear to be promising among these regimens,
with a pathological complete response rate of 25% [27].
Therefore, future RCTs using these three-drug protocols
for NCT are warranted. In addition, proper staging in




















Dautzenberg et al. 10 1985 to 1987 1990 26 European No details given Not reported Full text Stage 1 to 3 81 VCP × 2 1.10 (0.41 to 2.93)
Roth et al. 13,14 1987 to 1993 1998 60 US No details given Not reported Full text Stage 3 only 37 CEP × 3 0.56 (0.31 to 1.01)
Rosell et al. 11, 12 1989 to 1991 1999 60 European Details given Not reported Full text Stage 3 only 70 MIP × 3 0.50 (0.30 to 0.85)
Zhou et al. 21 1990 to 2001 2001 624 Asian Details given Not reported Full text Stage 3 only 51 BAI/MVP/CAP/EP/
VIP/GP/NP/PC/TN× 2
0.87 (0.71 to 1.07)
De Pierre et al. 15 1991 to 1997 2002 355 European No details given Reported Full text Stage 1 to 3 74 MIP × 2 0.83 (0.64 to 1.07)
JCOG 16 1993 to 1998 2003 62 Asian No details given Reported Full text Stage 3 only 24 VP× 3 1.19 (0.69 to 2.05)
Li et al. 24 1990 to 1995 2003 137 Asian No details given Not reported Full text Stage 3 only 80 CAP/EP× 1 0.68 (0.46 to 1.00)
Liao et al. 22 1995 to 1997 2003 211 Asian Details given Reported Full text Stage 1 to 3 - MVP/MAP× 2 1.06 (0.76 to 1.48)
Yao et al. 23 1990 to 2002 2004 456 Asian Details given Not reported Full text Stage 3 only 55 GP/NP/MVP/
EP × 2
0.83 (0.67 to 1.03)
Sorensen et al. 17 1998 to 2004 2005 90 US No details given Not reported Abstract Stage 1 to 3 - TP × 3 0.91 (0.55 to 1.50)
s9900 18,19 1999 to 2004 2006 336 European No details given Not reported Full text Stage 1 to 3 38 PC× 3 0.79 (0.60 to 1.06)
MRCLU22 6 1997 to 2005 2007 519 European No details given Not reported Full text Stage 1 to 3 49 MVP/MIP/NP/
PC/DC/GP × 3
1.02 (0.80 to 1.31)
Ch.E.S.T 20, 25 2000 to 2004 2008 270 European No details given Not reported Abstract Stage 1 to 3 41 GP × 3 0.63 (0.46 to 0.87)
Felip et al. 26 2000 to 2007 2010 409b European No details given Not reported Full text Stage 1 to 3 52 PC× 3 0.96 (0.84 to 1.10)
aHazard ratio for mortality.
bNumber of cases in surgery only, and neoadjuvant chemotherapy arms; excludes patients in the adjuvant chemotherapy arm.
BAI = bronchial artery infusion; CAP = cyclophosphamide, adriamycin, cisplatin; CEP = etoposide, cyclophosphamide, cisplatin; DC =docetaxel, carboplatin; EP = etoposide, cisplatin; GP = gemcitabine, cisplatin;
MAP=mitomycin, adriamycin, cisplatin; MIP =mitomycin, ifosfamide, cisplatin; MVP =mitomycin, vindesine, cisplatin; NP = navelbine, cisplatin; PC = paclitaxel, carboplatin; TN=paclitaxel, navelbine; VCP = vindesine,



















Table 2 Factors associated with benefit from neoadjuvant chemotherapy in non-small-cell lung cancer
Factors All trials Stage 1 to 3 (mixed-stage trials) Stage 3
B (95% CI)a P value B (95% CI) P value B (95% CI) P value
Disease characteristics
Histology (squamous cell fraction) −0.00 (−0.01 to 0.00) 0.600 0.00 (−0.01 to 0.01) 0.536 −0.00 (−0.01 to 0.00) 0.261








−0.03 (−0.09 to 0.14) 0.639 −0.04 (−0.19 to 0.11) 0.572 −0.09 (−0.16 to 0.34) 0.373
Number of drugs (2 vs 2
to 3 vs 3 drugs)
−0.01 (−0.09 to 0.06) 0.695 −0.03 (−0.04 to 0.11) 0.303 −0.18 (−0.27 to −0.08) 0.006
Number of chemotherapy cycles 0.00 (−0.09 to 0.10) 0.955 −0.04 (−0.19 to 0.11) 0.572 −0.01 (−0.23 to 0.21) 0.871
Trial characteristics
Trial sized 0.00 (−0.01 to 0.01) 0.569 −0.00 (−0.02 to 0.01) 0.530 0.01 (−0.02 to 0.03) 0.514
Publication year 0.01 (−0.01 to 0.02) 0.605 −0.00 (−0.02 to 0.01) 0.535 0.03 (−0.03 to 0.09) 0.215
Origin of study (European vs
Asian vs US)
−0.01 (−0.10 to 0.08) 0.885 0.03 (−0.09 to 0.15) 0.566 0.03 (−0.03 to 0.34) 0.841
Trial quality scoree 0.03 (−0.04 to 0.09) 0.373 0.04 (−0.03 to 0.10) 0.186 0.12 (−0.16 to 0.40) 0.300
aRegression coefficient and 95% confidence interval.
bNot relevant.
cAnalysis not performed due to insufficient number of trials in that subgroup.
dSquare root transformation. For analyses for trial size, analyses have not been weighed for trial size.
eOver a scale from 0 to 3, depending on randomization method (details given vs not given), stratification criteria (reported vs not reported) and trial type
(reported in full text or abstract).
R2 = 0.27 
R2 = 0.92 
Figure 1 Number of drugs in the neoadjuvant protocol and risk of death with respect to stage of non-small-cell lung cancer. This figure
shows the activity of different numbers of chemotherapy drugs in the neoadjuvant chemotherapy protocol in different stages of disease.
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tinum before and after NCT, with positron emission
tomography-computed tomography (PET-CT), other im-
aging modalities, and invasive and non-invasive means
of pathological mediastinal evaluation better helping to
properly quantify the amount of benefit from these
protocols.
Obviously, predictive biomarker studies integrated
within NCT trials are also of great importance, as some
potential predictive markers have been shown to be of
use in metastatic NSCLC. ERCC1 and RRM1 are two
such markers that have been linked with the benefit of
cisplatin and gemcitabin based protocols, respectively
[29,30]. We think integrating different biomarkers and
genomic profiling in treatment protocols of stage 3
NSCLC is also very important, since the disease biology
and available treatment options in this setting are het-
erogeneous and each patient should be carefully evalu-
ated on an individual basis to tailor the best treatment.
A limitation of this study is the long time period from
which the trials included in the study were collected
(from 1990 to 2010). Staging techniques and treatment
protocols may have changed during this period of time;
therefore one has to be aware of this fact when making
comparisons between different studies. Particularly, inte-
gration of PET/CT into staging investigations has con-
siderably changed routine clinical practice for patients
with NSCLC, and future neoadjuvant studies have to
make good use of invasive and non-invasive methods of
staging, accordingly.
In a previous study, our group had investigated the
correlates of benefit from neoadjuvant chemotherapy be-
fore radiotherapy in NSCLC; our current attempt
extends this effort to the benefit of NCT before surgery
[31]. Because personalizing treatment in stage 3 disease
would also require various predictive markers in the
context of different treatment settings, just as in stage 4
disease, predictive markers that are of proven benefit
will be readily welcomed by thoracic oncologists.
It is interesting that in our analysis, the benefit from
NCT was not different with respect to the stage of dis-
ease. In addition, an indirect methodology meta-analysis
had shown that NCT was similar to adjuvant chemo-
therapy in terms of survival benefit provided [32]. These
findings taken together suggest that when chemotherapy
is indicated in stage 2 or 3 disease, NCT or adjuvant
chemotherapy are reasonable options in suitable
patients. It may be NCT is more beneficial for patients
with borderline performance status before surgery, as
performance may be expected to decline further after
surgery in some patients, making adjuvant chemother-
apy harder to administer [6].
In short, this literature-based analysis suggests that
NCT with protocols containing three drugs is morebeneficial in stage 3 NSCLC than protocols with a lesser
number of agents. An individual patient data meta-
analysis testing this hypothesis is eagerly awaited; also,
RCTs with third-generation drugs and three agents for
NCT should be conducted separately for stage 3 disease.
Conclusions
In this analysis of 14 RCTs of neoadjuvant chemotherapy
before surgery, we show that in the setting of stage 3
NSCLC inclusion of 3 chemotherapy drugs in the treat-
ment protocol is associated with less mortality. An indi-
vidual patient data meta-analysis, as well as new RCTs,
are needed to comment further on this issue.
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